Half-dose for Halcygen
Tuesday, 07 October, 2008
Halcygen Pharmaceuticals (ASX: HGN) has demonstrated the effectiveness of the company's SUBA-itraconazole antifungal in a recent pharmacokinetic trial.
The trial was the first of three pharmacokinetic studies the company is conducting for the Investigational New Drug [IND] application recently approved by the FDA.
Halcygen was able to prove that SUBA-itraconazole in a 'half-dose' format gives comparable pharmacokinetic levels to a full dose of itraconazole market leader Sporanox.
All three pharmacokinetic trials should be complete by the end of the year.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
